09/09/2016
Great news for HCAR tenant Apogee Biotech: RedHill Biopharma Announces Phase Ib/II Study with YELIVA™ Initiated... http://bit.ly/2c5p7BF
TEL-AVIV, Israel, Sept. 08, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule